Moderna exec: Its COVID-19 vaccine likely provides immunity for a year

/ / News

Moderna Inc. expects its COVID-19 vaccine to provide immunity to the virus for at least a year, according to remarks made by a company executive at an investor conference on Monday. Shares of Moderna Inc. were up 0.8% in premarket trading on Tuesday. Moderna developed one of the two authorized COVID-19 vaccines in the U.S. The company is tracking antibodies in participants in its Phase 1, 2, and 3 clinical trials to better understand what level of antibodies are needed to be protected against infection with the coronavirus. “Our expectation is that the vaccination should last you at least a year to the degree that you need a booster shot,” the executive said. (It’s unclear who was speaking based on the FactSet transcript of the meeting at the J.P. Morgan Healthcare Conference.) Moderna’s stock has rallied 512.6% so far this year, while the S&P 500 is up 17.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.